Related Experiment Video
Updated: Jul 5, 2026
03:47
Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid
Published on: September 27, 2024
A synthetic hexapeptide (Argireline) with antiwrinkle activity
C Blanes-Mira1, J Clemente, G Jodas
1Centro Biología Molecular y Celular, Universitas Miguel Hernández, 03202 Alicante, Spain.
International Journal of Cosmetic Science
|May 24, 2008
Summary
Argireline, a novel hexapeptide, effectively reduces wrinkle depth by inhibiting neurotransmitter release, offering a safe alternative to Botulinum neurotoxins (BoNTs) in cosmetic applications.
Area of Science:
- Cosmetic Science
- Molecular Biology
- Dermatology
Background:
- Botulinum neurotoxins (BoNTs) are effective anti-wrinkle agents but limited by high neurotoxicity.
- Development of non-toxic molecules mimicking BoNTs' action is crucial for cosmetic applications.
Purpose of the Study:
- To evaluate the anti-wrinkle efficacy and safety of the hexapeptide Argireline.
- To elucidate the mechanism of action of Argireline in comparison to BoNTs.
Main Methods:
- Rational drug design to identify Argireline (Ac-EEMQRR-NH(2)).
- Skin topography analysis on volunteers treated with an Argireline emulsion.
- In vitro analysis of neurotransmitter release and SNARE complex interaction.
- In vivo toxicity and irritation tests.
Main Results:
- A 10% Argireline emulsion reduced wrinkle depth by up to 30% in 30 days.
- Argireline inhibited neurotransmitter release, mimicking BoNT A's potency but with lower efficacy.
- The peptide interfered with SNARE complex formation/stability, inhibiting Ca(2+)-dependent exocytosis.
- Argireline showed no in vivo oral toxicity or primary irritation at high doses.
Conclusions:
- Argireline is a non-toxic, anti-wrinkle peptide that emulates BoNT action.
- This hexapeptide represents a biosafe and effective alternative to BoNTs in cosmetic formulations.
Related Concept Videos
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...